Novartis Ag (NVS) Gains from Investment Securities (2009 - 2026)

Novartis Ag (NVS) has 16 years of Gains from Investment Securities data on file, last reported at -$787.0 million in Q1 2026.

• Quarterly Gains from Investment Securities fell 45.74% year-over-year to -$787.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$2.8 billion (down 26.42% YoY) and the FY2025 annual result came in at -$981.0 million, changed N/A from the prior year.
• Gains from Investment Securities grew to -$787.0 million in Q1 2026 per NVS's latest filing, from -$981.0 million in the prior quarter.
• The five-year high for Gains from Investment Securities was -$260.0 million in Q3 2022, with the low at -$1.3 billion in Q4 2023.
• Average Gains from Investment Securities over 5 years is -$611.9 million, with a median of -$576.0 million recorded in 2024.
• Year-over-year, Gains from Investment Securities soared 62.17% in 2022 and slumped 279.64% in 2023.
• Novartis Ag's Gains from Investment Securities stood at -$334.0 million in 2022, then tumbled by 279.64% to -$1.3 billion in 2023, then climbed by 27.13% to -$924.0 million in 2024, then slipped by 6.17% to -$981.0 million in 2025, then gained by 19.78% to -$787.0 million in 2026.
• Business Quant data shows NVS's Gains from Investment Securities at -$787.0 million in Q1 2026, -$981.0 million in Q4 2025, and -$366.0 million in Q3 2025.